A two-day meeting aimed at raising awareness among policymakers and public about rare diseases scheduled for the end of the ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list ...

Staff units evaluating high-tech surgical robots and insulin-delivery systems were gutted by Trump layoffs even though ...

A two-day meeting aimed at raising awareness among policymakers and the public about rare diseases scheduled for the end of ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The U.S. Food and Drug Administration (FDA) began 2025 with a resolution to make food “healthy” again by announcing a trio of new final and ...

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and ...